<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083576</url>
  </required_header>
  <id_info>
    <org_study_id>PG-PANAMA-08-04; A-15810</org_study_id>
    <nct_id>NCT01083576</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama</brief_title>
  <official_title>Double-blind, Randomized, Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are to evaluate the pharmacokinetics (PK), safety, and efficacy
      of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream in
      subjects with cutaneous leishmaniasis (CL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-site, randomized, double-blind, two group trial assessing the PK,
      safety and efficacy of WR 279,396 Topical Cream and Paromomycin Topical Cream in subjects
      with CL. Subjects will be screened over a period up to 28 days for eligibility including
      parasitology for confirmation of ulcerative CL. Subjects will be randomized in a targeted 1:1
      ratio to receive either WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) (target
      n=15) or Paromomycin Topical Cream (15% paromomycin topical cream) (target n=15) by topical
      application to CL lesions once daily for 20 days. Because the primary objective of this trial
      is to determine PK in all age groups, subjects will be stratified by age: 5-11 yrs, 12-17
      yrs, and ≥ 18 yrs with at least 6 PK subjects in each age stratum and no more than 18 total
      subjects will be randomized in any age range. A target of 30 subjects who complete the PK
      part of the study is the goal. Any subject who does not complete the PK portion of the study
      will be replaced with another subject from the same age group that will be given the same
      treatment assignment to maintain the balance. Safety will be assessed by monitoring adverse
      events (AEs), lesion site reactions, vital signs, and blood creatinine levels. The primary
      efficacy analysis will be by evaluation of an index lesion with secondary efficacy analyses
      including all lesions. Lesions will also be examined for parasite negativity by classical
      means (positive culture for promastigotes or microscopic identification of amastigotes in
      stained lesion tissue) on Day 21.

      In adult subjects, on Days 1 and 20, blood will be collected prior to topical cream
      application and at 0.5h, 1h, 2h, 3h, and 4h ± 5 minutes and 8h, 12h, and 24h ± 15 minutes
      after completion of cream application to determine plasma levels of paromomycin and
      gentamicin to calculate PK parameters. Thus, the last blood draw in this series will occur on
      Day 21. In addition, blood will be collected on Days 4, 7, 12, and 17 ± 1 day before study
      drug application to examine trough plasma levels of paromomycin and gentamicin. A follow-up
      plasma sample for PK analysis will also be obtained on Day 28 ± 2 days.

      Subjects under the age of 18 years will have a total of four blood samples drawn. The first
      will be drawn at pre-application and the second will be drawn at 4 hours ± 5 minutes after
      completion of application of the topical cream on Study Day 1. The third will be drawn
      pre-application and the fourth at 4 hours ± 5 minutes after completion of application of the
      topical cream on Study Day 20. Subjects who receive Paromomycin Topical Cream are not
      expected to have blood levels of gentamicin, but as the study is blinded, plasma specimens
      will be tested for both paromomycin and gentamicin.

      The index lesion (primary ulcerated) and all other ulcerated lesions will be assessed for
      clinical response by measurement of the length and width of area of ulceration. A lesion will
      be considered to be completely cured if 100% re-epithelialization is observed (i.e., this is
      a measurement of ulceration of 0 x 0 mm). Non-ulcerated lesions will also be measured to
      monitor the total area of exposure of lesions to study drug and will be evaluated for cure
      (i.e., absence of signs of an active lesion).

      Subjects will have an in-clinic follow-up weekly (Days 28, 35, 42, 49, 56, and 63 ± 2 days)
      after completion of treatment for safety assessments, lesion measurements, and lesion
      photographs. On Day 21, index lesions in adult subjects that have not completely
      re-epithelialized will be assessed for parasites by classical means (positive culture for
      promastigotes or microscopic identification of amastigotes in stained lesion tissue). An
      interim analysis of all of the data collected on all subjects who were randomized and
      completed the nominal Day 63 follow-up will be performed to make decisions about the final
      design of a Phase 3 trial. Subjects will continue to be followed for outcomes at Day 100 and
      168 ± 14 days. A final analysis of outcomes after the longer term followup period has been
      completed for all subjects will be performed when the trial is closed. Follow-up evaluations
      include AEs, medication use, lesion measurements, and lesion photographs.

      Patients who fail therapy (see definition of failure below) may be administered rescue
      therapy at the discretion of the patient's personal physician.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Obtained Final Clinical Cure of Index Lesion</measure>
    <time_frame>168 days</time_frame>
    <description>Number of participants who had initial clinical cure (100% re-epithelialization of index lesion by Day 63) OR initial clinical improvements (&gt; 50% re-epithelialization of index lesion followed by Day 63 by 100% re-epithelialization of the index lesion on or before Day 100), AND no relapse of index lesion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Obtained a Modified Final Clinical Cure of All Lesions</measure>
    <time_frame>168 days</time_frame>
    <description>Final cure as defined by the primary outcome measure AND and cure of all other lesions by Day 168. (100% re-epithelialization of all ulcerated lesions and resolution of all other type of lesions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detectable Paromomycin or Gentamicin Plasma Levels</measure>
    <time_frame>20 days</time_frame>
    <description>Proportion of subjects with any detectable Paromomycin or Gentamicin plasma levels on a study day when blood for PK was collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paromomycin Plasma Concentrations in Adults</measure>
    <time_frame>Day 4 to Day 28</time_frame>
    <description>Paromomycin plasma concentrations following administration of paromomycin alone or WR 279,396 in adults</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paromomycin Plasma Concentrations in Children</measure>
    <time_frame>Days 1 and 20</time_frame>
    <description>Paromomycin plasma concentrations 4 hours following administration of paromomycin alone or WR 279,396 in children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Cmax</measure>
    <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
    <description>Cmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Tmax</measure>
    <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
    <description>Tmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Area Under the Curve (AUC)</measure>
    <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
    <description>Area under the curve (AUC) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: t(1/2)</measure>
    <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
    <description>t(1/2) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Cmax/D</measure>
    <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
    <description>Maximum observed plasma concentration divide by topical dose (Cmax/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: AUC/D</measure>
    <time_frame>Days 1 and 20</time_frame>
    <description>Area under the plasma concentration-time curve over 24 hrs divided by topical dose (AUC/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Creatinine Levels</measure>
    <time_frame>Day 1 and Day 20</time_frame>
    <description>Blood creatinine was measured to assess possible nephrotoxicity associated with aminoglycosides</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Leishmaniasis, Cutaneous</condition>
  <arm_group>
    <arm_group_label>Paromomycin Alone Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated cutaneous leishmaniasis (CL) lesions once daily for 20 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WR 279,396</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)</intervention_name>
    <description>topical application to CL lesions once daily for 20 days</description>
    <arm_group_label>WR 279,396</arm_group_label>
    <other_name>Topical paromomycin/gentimicin cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paromomycin Alone Cream (15% paromomycin topical cream)</intervention_name>
    <description>topical application to CL lesions once daily for 20 days</description>
    <arm_group_label>Paromomycin Alone Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be eligible for the study, the following must be answered &quot;YES&quot; or not applicable,
             as appropriate for the study subject:

               1. Is the subject a male or female at least 5 years-of-age?

               2. Is the subject or legal guardian able to give written informed consent or assent,
                  as appropriate?

               3. Does the subject have a diagnosis of CL in at least one lesion by at least one of
                  the following methods: 1) positive culture for promastigotes, or 2) microscopic
                  identification of amastigotes in stained lesion tissue.

               4. Does the subject have at least one ulcerative lesion ≥ 1 cm and ≤ 5 cm, that
                  meets the criteria for an index lesion?

               5. Is the subject willing to forego other forms of treatments for CL including other
                  investigational treatments during the study?

               6. In the opinion of the investigator, is the subject (or their legal guardian)
                  capable of understanding and complying with the protocol?

               7. If female and of child-bearing potential, did the subject have a negative
                  pregnancy test during screening and agree to use an acceptable method of birth
                  control during the treatment phase and for 1 month after treatment is completed?

               8. Does the subject have adequate venous access for blood draws?

        Exclusion Criteria:

        To be eligible for the study, the following must be answered &quot;NO&quot; or not applicable as
        appropriate for the study subject:

          1. Does the subject have only a single lesion whose characteristics include any of the
             following: verrucous or nodular lesion (non-ulcerative), lesion &lt;1 cm in its greatest
             diameter, lesion in a location that in the opinion of the Investigator is difficult to
             maintain application of study drugs topically?

          2. Does the subject have a lesion due to leishmania that involves the mucosa or palate or
             any signs of mucosal disease that might be due to leishmania?

          3. Does the subject have signs and symptoms of disseminated disease in the opinion of the
             Principal Investigator?

          4. Does the subject have &gt; 10 lesions?

          5. Is the subject a female who is breast-feeding?

          6. Does the subject have an active malignancy or history of solid, metastatic or
             hematologic malignancy with the exception of basal or squamous cell carcinoma of the
             skin that has been removed?

          7. Does the subject have significant organ abnormality, chronic disease such as diabetes,
             severe hearing loss, evidence of renal or hepatic dysfunction, or creatinine,
             aspartate aminotransferase (AST), or alanine aminotransferase (ALT) greater than 15%
             above the upper limit of normal (ULN) as defined by the clinical laboratory defined
             normal ranges?

          8. Has the subject received treatment for leishmaniasis including any medication with
             pentavalent antimony including sodium stibogluconate (Pentostam), meglumine
             antimoniate (Glucantime); amphotericin B (including liposomal amphotericin B and
             amphotericin B deoxycholate); or other medications containing paromomycin
             (administered parenterally or topically) or methylbenzethonium chloride (MBCL);
             gentamicin; fluconazole; ketoconazole; pentamidine; miltefosine, azithromycin or
             allopurinol that was completed within 8 weeks of starting study treatments?

          9. Does the subject have a history of known or suspected hypersensitivity or
             idiosyncratic reactions to aminoglycosides?

         10. Does the subject have any other topical disease/condition which would interfere with
             the objectives of this study?
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nestor Sosa, M.D. FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Conmemorativo Gorgas de Estudios de la Salud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gorgas Memorial Institute Clinical Research Unit</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <results_first_submitted>November 20, 2013</results_first_submitted>
  <results_first_submitted_qc>April 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 15, 2014</results_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leishmaniasis</keyword>
  <keyword>cutaneous</keyword>
  <keyword>WR 279,396</keyword>
  <keyword>paromomycin</keyword>
  <keyword>gentamicin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Paromomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paromomycin Alone Treatment</title>
          <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated cutaneous leishmaniasis (CL) lesions once daily for 20 days</description>
        </group>
        <group group_id="P2">
          <title>WR 279,396</title>
          <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects were included in the mITT Analysis. All subjects met criteria for the evaluable subset.</population>
      <group_list>
        <group group_id="B1">
          <title>Paromomycin Alone Treatment</title>
          <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
        </group>
        <group group_id="B2">
          <title>WR 279,396</title>
          <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.0" spread="16.2"/>
                    <measurement group_id="B2" value="25.5" spread="15.9"/>
                    <measurement group_id="B3" value="24.7" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mestizo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" spread="100"/>
                    <measurement group_id="B2" value="15" spread="93.3"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Obtained Final Clinical Cure of Index Lesion</title>
        <description>Number of participants who had initial clinical cure (100% re-epithelialization of index lesion by Day 63) OR initial clinical improvements (&gt; 50% re-epithelialization of index lesion followed by Day 63 by 100% re-epithelialization of the index lesion on or before Day 100), AND no relapse of index lesion.</description>
        <time_frame>168 days</time_frame>
        <population>All randomized subjects were included in the mITT Analysis. All subjects met criteria for the evaluable subset.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Obtained Final Clinical Cure of Index Lesion</title>
          <description>Number of participants who had initial clinical cure (100% re-epithelialization of index lesion by Day 63) OR initial clinical improvements (&gt; 50% re-epithelialization of index lesion followed by Day 63 by 100% re-epithelialization of the index lesion on or before Day 100), AND no relapse of index lesion.</description>
          <population>All randomized subjects were included in the mITT Analysis. All subjects met criteria for the evaluable subset.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Obtained a Modified Final Clinical Cure of All Lesions</title>
        <description>Final cure as defined by the primary outcome measure AND and cure of all other lesions by Day 168. (100% re-epithelialization of all ulcerated lesions and resolution of all other type of lesions)</description>
        <time_frame>168 days</time_frame>
        <population>All randomized subjects were included in the mITT Analysis. All subjects met criteria for the evaluable subset.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Obtained a Modified Final Clinical Cure of All Lesions</title>
          <description>Final cure as defined by the primary outcome measure AND and cure of all other lesions by Day 168. (100% re-epithelialization of all ulcerated lesions and resolution of all other type of lesions)</description>
          <population>All randomized subjects were included in the mITT Analysis. All subjects met criteria for the evaluable subset.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Detectable Paromomycin or Gentamicin Plasma Levels</title>
        <description>Proportion of subjects with any detectable Paromomycin or Gentamicin plasma levels on a study day when blood for PK was collected</description>
        <time_frame>20 days</time_frame>
        <population>Adults ages &gt;= 17 years</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Detectable Paromomycin or Gentamicin Plasma Levels</title>
          <description>Proportion of subjects with any detectable Paromomycin or Gentamicin plasma levels on a study day when blood for PK was collected</description>
          <population>Adults ages &gt;= 17 years</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any detectable gentamicin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any detectable paromomycin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Paromomycin Plasma Concentrations in Adults</title>
        <description>Paromomycin plasma concentrations following administration of paromomycin alone or WR 279,396 in adults</description>
        <time_frame>Day 4 to Day 28</time_frame>
        <population>Adults ages &gt;= 17 years</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated cutaneous leishmaniasis (CL) lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Paromomycin Plasma Concentrations in Adults</title>
          <description>Paromomycin plasma concentrations following administration of paromomycin alone or WR 279,396 in adults</description>
          <population>Adults ages &gt;= 17 years</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="17.8" spread="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="37.1"/>
                    <measurement group_id="O2" value="17.6" spread="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="18.8"/>
                    <measurement group_id="O2" value="26.4" spread="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" spread="49.8"/>
                    <measurement group_id="O2" value="26.3" spread="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.6" spread="48.4"/>
                    <measurement group_id="O2" value="31.4" spread="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Paromomycin Plasma Concentrations in Children</title>
        <description>Paromomycin plasma concentrations 4 hours following administration of paromomycin alone or WR 279,396 in children</description>
        <time_frame>Days 1 and 20</time_frame>
        <population>Children ages 7 to 16</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Paromomycin Plasma Concentrations in Children</title>
          <description>Paromomycin plasma concentrations 4 hours following administration of paromomycin alone or WR 279,396 in children</description>
          <population>Children ages 7 to 16</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.3" spread="83.6"/>
                    <measurement group_id="O2" value="98.6" spread="132.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="992.7" spread="1149.7"/>
                    <measurement group_id="O2" value="634.2" spread="426.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: Cmax</title>
        <description>Cmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
        <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
        <population>Adults with measurable samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: Cmax</title>
          <description>Cmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
          <population>Adults with measurable samples.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.0" spread="294"/>
                    <measurement group_id="O2" value="121" spread="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="751.0" spread="609.0"/>
                    <measurement group_id="O2" value="561.0" spread="560.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: Tmax</title>
        <description>Tmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
        <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
        <population>Adults ages &gt;= 17 years with measurable samples. Both groups had only 6 measureable samples each on Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: Tmax</title>
          <description>Tmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
          <population>Adults ages &gt;= 17 years with measurable samples. Both groups had only 6 measureable samples each on Day 1.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.2"/>
                    <measurement group_id="O2" value="2.8" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.8"/>
                    <measurement group_id="O2" value="2.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: Area Under the Curve (AUC)</title>
        <description>Area under the curve (AUC) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
        <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
        <population>Adults ages &gt;= 17 years with measurable samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: Area Under the Curve (AUC)</title>
          <description>Area under the curve (AUC) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
          <population>Adults ages &gt;= 17 years with measurable samples.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1571" spread="1850"/>
                    <measurement group_id="O2" value="863.4" spread="974.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5603" spread="4050"/>
                    <measurement group_id="O2" value="4740" spread="3987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Creatinine Levels</title>
        <description>Blood creatinine was measured to assess possible nephrotoxicity associated with aminoglycosides</description>
        <time_frame>Day 1 and Day 20</time_frame>
        <population>All randomized subjects were included in the mITT Analysis. All subjects met criteria for the evaluable subset.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine Levels</title>
          <description>Blood creatinine was measured to assess possible nephrotoxicity associated with aminoglycosides</description>
          <population>All randomized subjects were included in the mITT Analysis. All subjects met criteria for the evaluable subset.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.23"/>
                    <measurement group_id="O2" value="0.79" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.26"/>
                    <measurement group_id="O2" value="0.76" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: t(1/2)</title>
        <description>t(1/2) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
        <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
        <population>Adults ages &gt;= 17 years with measurable samples. Paromomycin Alone Treatment had only 5 measureable samples on Day 1, and WR 279,396 had only 4 measureable samples on Day 20.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: t(1/2)</title>
          <description>t(1/2) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
          <population>Adults ages &gt;= 17 years with measurable samples. Paromomycin Alone Treatment had only 5 measureable samples on Day 1, and WR 279,396 had only 4 measureable samples on Day 20.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.03" spread="7.67"/>
                    <measurement group_id="O2" value="4.0" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="2.1"/>
                    <measurement group_id="O2" value="7.0" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: Cmax/D</title>
        <description>Maximum observed plasma concentration divide by topical dose (Cmax/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
        <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
        <population>Adults ages &gt;= 17 years with measurable samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated cutaneous leishmaniasis (CL) lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: Cmax/D</title>
          <description>Maximum observed plasma concentration divide by topical dose (Cmax/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
          <population>Adults ages &gt;= 17 years with measurable samples.</population>
          <units>1/ML</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.0" spread="104.0"/>
                    <measurement group_id="O2" value="61.3" spread="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227" spread="71"/>
                    <measurement group_id="O2" value="179" spread="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: AUC/D</title>
        <description>Area under the plasma concentration-time curve over 24 hrs divided by topical dose (AUC/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
        <time_frame>Days 1 and 20</time_frame>
        <population>Adults ages &gt;= 17 years with measurable samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated cutaneous leishmaniasis (CL) lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: AUC/D</title>
          <description>Area under the plasma concentration-time curve over 24 hrs divided by topical dose (AUC/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
          <population>Adults ages &gt;= 17 years with measurable samples.</population>
          <units>hr/ML</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="715.2" spread="748.1"/>
                    <measurement group_id="O2" value="345.9" spread="303.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1725" spread="530"/>
                    <measurement group_id="O2" value="1380" spread="631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Paromomycin Alone Treatment</title>
          <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
        </group>
        <group group_id="E2">
          <title>WR 279,396</title>
          <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Application site oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Superinfection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mucocutaneous leishmaniasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There are no PK tables for gentamicin due to low sample size; only 2 individuals with measureable gentamicin.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director, Division of Regulated Activites and Compliance</name_or_title>
      <organization>US Army Medical Materiel Development Activity (USAMMDA)</organization>
      <phone>301-619-0197</phone>
      <email>usarmy.detrick.medcom-usammda.mbx.usamrmc-regulatory-affairs@mail.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

